This study is currently not recruiting participants.

A Phase 2 Open-Label Multiple-Dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Pharmacodynamics of NBI-74788 in Adult Subjects with Congenital Adrenal Hyperplasia

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to assess the safety and tolerability NBI-74788 in adults with CAH and to measure the amount of study drug, and learn about the effects of the study drug through measuring substances (biomarkers) in your blood, following repeated doses of NBI-74788.

Description

The purpose of this research study is: -To assess the safety and tolerability of 2 doses of NBI-74788 (given as 50 mg or 100 mg) in adults with CAH. The first 8-10 subjects enrolled in the study will receive a 50 mg dose per day. The second 8-10 subjects enrolled in the study will receive a 100 mg dose per day. -To measure the amount of study drug, and learn about the effects of the study drug through measuring biomarkers, following repeated doses of NBI-74788.

Details
Condition Congenital Adrenal Hyperplasia (CAH)
Age 18years - 50years
Clinical Study IdentifierTX8844
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.